Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00372853 · ClinicalTrials.gov registry record · Phase 1

Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma

A Phase 1 study, sponsored by AstraZeneca.

Completed
Registry status
Phase 1
Development phase
28
Enrollment target

NCT00372853: Completed Phase 1 study, sponsored by AstraZeneca.

NCT00372853 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 28 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00372853, a Phase 1 study, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 1
Development phase
28 participants
Enrollment target

Study Summary

This study will determine the highest tolerable dose of CP-675,206 when given in combination with SU011248.

Interventions

  • DRUG SU011248
  • DRUG CP-675,206

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2006-11
Est. Completion 2010-05
Phase Phase 1
AstraZeneca

1,285 total trials

What the finished NCT00372853 record still lists

NCT00372853 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower).

The record links to 0 conditions, and to 2 interventions - of which SU011248 is the first listed.

NCT00372853 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00372853 about?

NCT00372853 is a clinical study titled "Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma". This study will determine the highest tolerable dose of CP-675,206 when given in combination with SU011248.

What is the current status of trial NCT00372853?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2006-11. Estimated completion is 2010-05.

What interventions are being tested in trial NCT00372853?

The interventions under investigation include: SU011248 (DRUG), CP-675,206 (DRUG).

Who is sponsoring clinical trial NCT00372853?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00372853's enrollment target sits among peer trials

28 1447th of 2000 higher than 538 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03471117 · 28 participants · Phase 4

    Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients

  • NCT03523975 · 28 participants · Phase 1

    Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

  • NCT03608631 · 28 participants · Phase 1

    iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation

  • NCT03810651 · 28 participants · Early Phase 1

    Pencil Beam Scanning in Patients With Renal Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00372853, the US trial registry maintained by the National Library of Medicine. NCT00372853 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.